Official ESCRS | European Society of Cataract & Refractive Surgeons
Copenhagen 2016 Registration Programme Exhibitor Information Virtual Exhibition Satellite Meetings Glaucoma Day 2016 Hotel Star Alliance

10 - 14 Sept. 2016, Bella Center, Copenhagen, Denmark

This Meeting has been awarded 27 CME credits


escrs app advert yo advert

Personal experience and outcomes through one year following implantation of second generation trabecular micro-bypass stents in patients with open-angle glaucoma

Search Title by author or title

Session Details

Session Title: Glaucoma I

Session Date/Time: Sunday 11/09/2016 | 14:30-16:00

Paper Time: 15:06

Venue: Auditorium C6

First Author: : F.Hengerer GERMANY

Co Author(s): :    T. Kohnen   I. Conrad-Hengerer                 

Abstract Details


The purpose of this work is to summarize findings through 1 year postoperative in patients with open-angle glaucoma following implantation of second generation trabecular micro-bypass stents.


Department of Ophthalmology, Goethe-University Frankfurt am Main, Frankfurt, Germany


This was a consecutive series of cases in which the iStent inject (Glaukos), a second generation trabecular micro-bypass stent, was implanted. Twenty-nine phakic or pseudophakic eyes of 22 patients with open-angle glaucoma (OAG) received two iStent inject devices as a sole procedure. The stents were implanted ab internally into Schlemm’s canal through a clear corneal incision using a single insertion instrument. A preoperative exam and postoperative exams through 1 year included assessment of IOP and medication use, and safety assessments including best corrected visual acuity (BCVA), cup-disk (C/D) ratio, complications, and secondary surgeries


Mean preoperative age was 71.1 ± 10.8 years, mean C/D ratio was 0.8 ± 0.1, and mean IOP was 24.3 ± 4.9 mmHg. Eighty-three percent of eyes used 3 or 4 medications; 38% had prior glaucoma surgery. Patients underwent implantation of 2 iStent inject devices without surgical complications. Mean IOP decreased to 13.8 ± 1.8 mmHg at one year, and mean medication use decreased by 2.4 medications from 2.8 preoperatively. At 1 year, 95% of eyes were using no or 1 medication. Postoperative progression of cataract was observed in 2 eyes; 95% of eyes had 1-year BCVA 20/40 or better.


Substantial reduction in both IOP and medication use and favorable safety was reported through 1 year postoperative following implantation of 2 iStent inject devices as the solitary surgical procedure in eyes with OAG not controlled by previous medical and/or surgical therapy. A 43% (10.5 mmHg) decrease from preoperative medicated mean IOP and an 86% decrease in medication burden was observed at 1 year.

Financial Disclosure:


Back to previous